Next Article in Journal
The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up
Previous Article in Journal
Aryl Hydrocarbon Receptor Activation Downregulates IL-33 Expression in Keratinocytes via Ovo-Like 1
Previous Article in Special Issue
The Role of Mitochondria in Inflammation: From Cancer to Neurodegenerative Disorders
Open AccessReview

Mitophagy in Cardiovascular Diseases

1
Maria Cecilia Hospital, GVM Care & Research, Via Corriera 1, Cotignola, 48033 Ravenna, Italy
2
Department of Medical Sciences, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, 44121 Ferrara, Italy
3
Neonatal Intensive Care Unit, University Hospital S. Anna Ferrara, 44121 Ferrara, Italy
4
Department of Clinical and Molecular Sciences, Marche Polytechnic University, 60126 Ancona, Italy
5
Neonatal Intensive Care Unit, Infermi Hospital Rimini, 47923 Rimini, Italy
6
Department of Medical Sciences, Section of General and Thoracic Surgery, University of Ferrara, 44121 Ferrara, Italy
7
Laboratory of Mitochondrial Biology and Metabolism, Nencki Institute of Experimental Biology of the Polish Academy of Sciences, 3 Pasteur Str., 02-093 Warsaw, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(3), 892; https://doi.org/10.3390/jcm9030892 (registering DOI)
Received: 5 March 2020 / Accepted: 15 March 2020 / Published: 24 March 2020
(This article belongs to the Special Issue The Rise of Mitochondria in Medicine)
Cardiovascular diseases are one of the leading causes of death. Increasing evidence has shown that pharmacological or genetic targeting of mitochondria can ameliorate each stage of these pathologies, which are strongly associated with mitochondrial dysfunction. Removal of inefficient and dysfunctional mitochondria through the process of mitophagy has been reported to be essential for meeting the energetic requirements and maintaining the biochemical homeostasis of cells. This process is useful for counteracting the negative phenotypic changes that occur during cardiovascular diseases, and understanding the molecular players involved might be crucial for the development of potential therapies. Here, we summarize the current knowledge on mitophagy (and autophagy) mechanisms in the context of heart disease with an important focus on atherosclerosis, ischemic heart disease, cardiomyopathies, heart failure, hypertension, arrhythmia, congenital heart disease and peripheral vascular disease. We aim to provide a complete background on the mechanisms of action of this mitochondrial quality control process in cardiology and in cardiac surgery by also reviewing studies on the use of known compounds able to modulate mitophagy for cardioprotective purposes. View Full-Text
Keywords: mitophagy; cardiovascular diseases; mitochondria; autophagy mitophagy; cardiovascular diseases; mitochondria; autophagy
Show Figures

Figure 1

MDPI and ACS Style

Morciano, G.; Patergnani, S.; Bonora, M.; Pedriali, G.; Tarocco, A.; Bouhamida, E.; Marchi, S.; Ancora, G.; Anania, G.; Wieckowski, M.R.; Giorgi, C.; Pinton, P. Mitophagy in Cardiovascular Diseases. J. Clin. Med. 2020, 9, 892.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop